Trofinetide Evidence Guide
Trofinetide (Daybue) is FDA-approved as the first treatment specifically indicated for Rett syndrome - a significant regulatory milestone for a devastating neurodevelopmental disorder. Phase 3 data from the LAVENDER trial showed statistically significant improvement on the Rett Syndrome Behaviour Questionnaire and clinician global impression scores. A landmark approval for a rare disease with no prior approved treatment.
Our Take
Trofinetide (Daybue) is FDA-approved as the first treatment specifically indicated for Rett syndrome - a significant regulatory milestone for a devastating neurodevelopmental disorder. Phase 3 data from the LAVENDER trial showed statistically significant improvement on the Rett Syndrome Behaviour Questionnaire and clinician global impression scores. A landmark approval for a rare disease with no prior approved treatment.
- Best for
- Rett syndrome (the approved indication), IGF-1/BDNF signaling in neurodevelopmental research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- Weight-based oral dosing per prescribing information (9g/day max, twice daily)
Benefits and Evidence
- Rett Syndrome Symptom Improvement: Level A, includes human evidence - Phase 3 LAVENDER trial showed statistically significant improvement in Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scores vs placebo.
- Communication and Behavior: Level B, includes human evidence - Improvements in communication, breathing irregularities, hand stereotypies, and ambulation reported across clinical trials, though individual response varies.
- Gastrointestinal Effects: Level A, includes human evidence - Diarrhea is the most common adverse effect, occurring in approximately 80% of patients. Weight loss also commonly reported, requiring nutritional monitoring.
Side Effects and Warnings
- Diarrhea (~80% of patients)
- Weight loss
- Vomiting
- Decreased appetite
- Upper respiratory tract infection
- Monitor weight and nutritional status closely - weight loss is common
- Diarrhea may require dose interruption or reduction
- Hepatic monitoring recommended during treatment
Research Dosage References
- <strong>Oral solution</strong> - 200 mg/kg - Twice daily - Weight-based dosing. Supplied as oral solution (200 mg/mL). Administered with or without food. Maximum single dose depends on body weight (capped at 12 g per dose for patients over 60 kg).
Mechanism of Action
Trofinetide acts as a neuroprotective and anti-neuroinflammatory agent: 1. IGF-1 tripeptide mimicry: Mimics the activity of GPE, the amino-terminal tripeptide naturally cleaved from IGF-1, which has independent neuroprotective properties. 2. Neuroinflammation reduction: Reduces microglial activation and neuroinflammatory signaling, which are elevated in Rett syndrome due to MECP2 gene dysfunction. 3. Synaptic function normalization: Promotes synaptic maturation and normalizes dendritic spine density and morphology, addressing the synaptic pathology underlying Rett syndrome. 4. Glial-neuronal signaling: Modulates pathological astrocyte and microglial interactions with neurons, restoring supportive glial functions.
Legal Status
FDA-approved (March 2023) for treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. Available by prescription only. Marketed as Daybue by Acadia Pharmaceuticals. Orphan drug designation.
Primary Sources
- Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study (LAVENDER). Nat Med, 2023.
- A phase 2 randomized clinical trial of trofinetide in Rett syndrome (DAFFODIL). Pediatr Neurol, 2019.
- GPE and trofinetide: neuroprotective mechanisms and clinical application in Rett syndrome. J Child Neurol, 2020.